International Isotopes, Inc.

I-131 Sodium Iodide & Other Radiochemicals

I-131 Sodium Iodide & Other Radiochemicals

International Isotopes Inc. (OTCQB: INIS) is proud to be the only FDA approved Sodium Iodide I-131 drug product manufactured in the United States…

EasyFill Automated Iodine Capsule System

EasyFill Automated Iodine Capsule System

This patented system allows for the hands-free preparation of iodine capsules, pairing perfectly with our iodine shielding and reducing radiation exposure.

RadQual Nuclear Medicine Products

Scintomics-ATT GRP Radiosynthesis Platform

International Isotopes distributes, installs, and services ATT’s state-of-the-art radiosynthesis modules, precursors and production sets throughout the United States and Canada.

RadQual Nuclear Medicine Products

Nuclear Medicine Calibration Standards

We manufacture a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems.

Cobalt Sealed Source Products

Cobalt Sealed Source Products

Our cobalt products are used by a broad array of companies for radiation treatment of cancer and vascular deformities of the brain. Cobalt sources are also used for container security examinations at our sea ports and borders.

LEA Calibration Sources & Radioactive Standards

Calibration Sources & Radioactive Standards

We are the North American distributor for LEA sources for control and calibration of equipment in the fields of radiation protection and metrology.

International Isotopes, Inc. Expands Operational Footprint with Strategic Land Acquisition and Additional New Facility Lease Agreement

INIS is excited to announce a strategic expansion of its company footprint with the recent purchase of vacant land adjacent to its current Idaho Falls facility (“Building A”). The Company has also entered a lease agreement, with the right to purchase the property, for a second building, which is located directly across the street from their Idaho Falls facility (“Building B”). These two forward-looking additions address both immediate needs for current operations and developing a comprehensive growth plan for the company.

Nuclear Shields

International Isotopes, Inc. Announces the Amendment of the Acquisition of the AMICI, Inc. Product Line

INIS will receive the manufacturing molds, device registrations, trademarks, and all production rights to the AMICI, Inc. line of Xenon System products as well as the registered intellectual property to Swirler® and Tru-Fit™ Mouthpiece products.

INIS Announces Exclusive Distributorship of Scintomics Moleculer/Applied Theranostics Technologies GmbH (ATT) Radiosynthesis Modules Throughout the U.S. and Canada

Under this agreement, International Isotopes will distribute, install, and service ATT’s state-of-the-art synthesis modules throughout the United States and Canada, along with providing consumables and ongoing support.

International Isotopes, Inc. Announces Financial Results for Third Quarter of 2024 and First Nine Months of 2024

  • Company Revenues increased by over $1,000,000, or 34%, for the Third Quarter compared to the
    prior year.
  • Theranostics Sales increased 42% compared the Third Quarter in the prior year.
  • The Company reported a net profit of $150,000 for the Third Quarter, an improvement of $497,000
    compared the Third Quarter in the prior year.
Nuclear Shields

International Isotopes, Inc. Announces Joint Venture Agreement to Form PhanQual

International Isotopes, Inc. (INIS) and Phantech Medical (Phantech) have entered into a joint venture agreement to form PhanQual, which will design, manufacture, and distribute long-lived calibration and reference sources for pre-clinical applications.

INIS and Alpha Nuclides Sign Strategic Development and Distribution Agreements For China

International Isotopes, Inc. (INIS) and Alpha Nuclide Inc (AN) have entered into a Strategic Development and Distribution Agreement for the rights to manufacture and distribute INIS’s Theranostics and nuclear Medicine Products in mainland China.